D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $34.0, a high estimate of $46.00 ...

D Molecular Therapeutics reaches agreement with FDA for phase 3 trial design of DME candidate 4D-150, showing promising ...

周一，BMO Capital Markets将4D Molecular Therapeutics (NASDAQ:FDMT)的评级从"跑赢大市"下调至"市场表现"，目标价定为$15.00。该股目前交易价格为$5.52，过去一年下跌近71%，接近其52周低点$5.22。

Analyst Matthew Caufield of H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), retaining the price ...

BofA lowered the firm’s price target on 4D Molecular (FDMT) to $42 from $46 on Friday and kept a Buy rating on the shares. The firm notes 4D ...

此次调整是在公司上周五宣布其管线更新后做出的。4D Molecular Therapeutics强调了其4D-150项目在湿性年龄相关性黄斑变性（wAMD）和糖尿病黄斑水肿（DME）治疗方面的优先地位，以及4D-710在囊性纤维化（CF）治疗方面的重要性。

After hours: January 13 at 6:56:49 PM EST Loading Chart for FDMT ...